ISSAR Pharmaceuticals

15/08/2022

Wishing you a very happy 75th Independence day

25/06/2022

26/01/2022

ISSAR Pharma wishes everyone a Happy Republic Day!

15/01/2022

01/01/2022

Wish you all a very Happy and Prosperous new year

04/11/2021

28/10/2021

A recent study published in the ‘Medicina’ Journal by the Multidisciplinary Digital Publishing Institute (MDPI), indicated that patients with psoriasis, administered with systemic therapy or other biologic treatments may experience a mild covid-19 infection and temporary exacerbation of psoriasis skin lesions.

Read More: https://issar.co.in/2021/10/28/psoriasis-patients-undergoing-biologic-other-systemic-therapies-may-experience-mild-sars-cov-2-infection/

Psoriasis patients undergoing biologic/other systemic therapies may experience mild SARS-CoV-2 infection A recent study published in the ‘Medicina’ Journal by the Multidisciplinary Digital Publishing Institute (MDPI), indicated that patients with…Continue readingPsoriasis patients undergoing b...

26/10/2021

CXCL9: A biomarker for Vitiligo activity

A recent study published in the ‘Nature’ scientific journal, proposed that the CXCL9 gene is a key biomarker for vitiligo activity and a significant predictor of the effectiveness of cultured melanocyte transplantation (CMT) for the treatment of vitiligo.

Read More: https://issar.co.in/2021/10/12/cxcl9-a-biomarker-for-vitiligo-activity

CXCL9: A biomarker for Vitiligo activity A recent study published in the ‘Nature’ scientific journal, proposed that the CXCL9 gene is a key biomarker for vitiligo activity and a significant predictor of…Continue readingCXCL9: A biomarker for Vitiligo activity

03/10/2021

29/09/2021

Inflammatory Bowel Diseases (IBD) currently affect approximately 0.5% of the Western world’s population. The globally occurring cases increased from 3.7 million to over 6.8 million between the years 1990 to 2017.
Issar has developed a novel non-biologic, non-steroidal, synthetic, small peptide of 10 amino acids paving a way for IBD treatment.

Read More:https://issar.co.in/2021/09/06/issars-is-217-for-inflammatory-bowel-diseases/

Inflammatory Bowel Diseases (IBD) currently affect approximately 0.5% of the Western world’s population. The globally occurring cases increased from 3.7 million to over 6.8 million between the years 1990 to 2017.…Continue readingISSAR’s IS-217 for Inflammatory Bowel Diseases